RecruitingDrug trialOpen Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeTo assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome